Raven, Wyeth Enter Antibody Pact

Raven Biotechnologies, Inc., has entered into an agreement with Wyeth Pharmaceuticals to develop and commercialize selected MAbs from Raven’s portfolio of antibodies to a specified target.

Under the terms of the agreement, Wyeth has the option to obtain an exclusive license to develop and commercialize therapies resulting from Raven’s designated antibodies. Terms of the agreement include an upfront payment, milestone payments and royalties based upon the net sales of products developed from the Raven technology.

The antibodies included in the agreement were discovered using Raven proprietary immunization technology and tumor-derived stem-cell lines, and were screened to select antibodies that are active alone or in a conjugated form.

“We are pleased to partner with Wyeth and believe this agreement further validates our approach,” said George F. Schreiner, M.D., Ph.D., Raven’s chief executive officer. “Raven’s proprietary antibody discovery processes rapidly create monoclonal antibodies and allow researchers to quickly assess the importance of those proteins in the disease process.”